Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura (COMPASS)

Avanir Pharmaceuticals

Status and phase

Completed

Phase 3

Conditions

Migraine

Headaches

Treatments

Drug: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally

Drug: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet

Study type

Interventional

Funder types

Industry

Identifiers

NCT01667679

OPN-SUM-MIG-3302

Details and patient eligibility

About

This study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN DEVICE can reduce the pain associated with migraine headaches in 30 minutes after use.

Full description

The primary objective for this study is to compare the proportion of attacks in which pain reduction (defined as a decrease in pain intensity of at least 1 point) is achieved at 30 minutes following 20 mg OPTINOSE SUMATRIPTAN treatment with 100 mg Sumatriptan Tablets

Enrollment

275 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Man or woman, between the ages of 18 to 65 years, inclusive at screening
Have a diagnosis of episodic migraine, with or without aura according to InternationalClassification of Headache Disorders (2nd Edition) (ICHD-2) for at least 1 year prior to screening
Experiences between 2 and 8 migraine attacks per month for the past 12 months
Women of child bearing potential must be practicing an effective method of birth control
Women of child-bearing potential must have a negative urine pregnancy test at the screening visit and a negative urine pregnancy test at the randomization visit
Demonstrate the ability to use the bi-directional delivery device correctly
Able and willing to read and comprehend written instructions and complete the electronic diary information required by the protocol
Must be capable, in the opinion of the Investigator, of providing informed consent to participate in the study. Subjects (and their legally acceptable representatives, if applicable) must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion criteria

Inability to distinguish other headaches from migraine
Experiences headache of any kind at a frequency greater than or equal to 15 days per month
History of resistance to sumatriptan, or non-response to 2 or more other triptans, defined as subjects who have not responded to an adequate dose and duration of treatment
Current use of medication for migraine prophylaxis that has not been stable (no dose adjustment) for 30 days prior to screening
Chronic opioid therapy (>3 consecutive days in the 30 days prior to screening)
Current treatment with monoamine oxidase A (MAO-A) inhibitors or use within 4 weeks before randomization
Have hemiplegic or basilar migraine
History, symptoms or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort, vasospastic forms of angina such as the Prinzmetal variant), all forms of myocardial infarction and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease, Raynaud syndrome
Uncontrolled hypertension (screening systolic/diastolic blood pressure >140/95 mmHg)
Have severe hepatic impairment
Have history of epilepsy or conditions associated with a lowered seizure threshold
History (within 2 years) of drug or alcohol abuse as defined by Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) criteria